替米沙坦联合阿托伐他汀对糖尿病合并冠心病患者心功能、糖脂代谢等相关指标的影响

Effect of Telmisartan Combined with Atorvastatin on Cardiac Function,Glycolipid Metabolism and Other Related Indicators in Patients with Diabetes and Coronary Heart Disease

目的:探究替米沙坦联合阿托伐他汀对糖尿病合并冠心病患者心功能、糖脂代谢等相关指标的影响。方法:选取2021年4月—2022年4月昆明医科大学附属昭通医院收治的96例糖尿病合并冠心病患者作为研究对象,随机将其分为对照组和观察组,各48例。对照组予以阿托伐他汀治疗,观察组予以替米沙坦联合阿托伐他汀治疗,两组均治疗2个月。比较两组治疗前、治疗2个月后心功能、糖脂代谢、炎症指标的差异性,并评价治疗安全性。结果:治疗2个月后,两组左室射血分数(LVEF)、舒张早期最大峰值速度(E峰)、E/舒张晚期最大峰值速度(A)、高密度脂蛋白胆固醇(HDL-C)高于治疗前,左室舒张末期内径(LVEDD)、A峰、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、C反应蛋白(CRP)、白细胞介素-8(IL-8)、白细胞介素-6(IL-6)水平低于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。两组各不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替米沙坦联合阿托伐他汀应用于糖尿病合并冠心病患者的治疗中,能促进心功能恢复,抑制炎症反应,降脂、降糖作用突出,且较为安全。

Objective:To explore the effect of Telmisartan combined with Atorvastatin on cardiac function,glycolipid metabolism and other related indicators in patients with diabetes and coronary heart disease.Method:A total of 96 patients with diabetes and coronary heart disease who admitted to Zhaotong Hospital Affiliated to Kunming Medical University from April 2021 to April 2022 were selected as the study objects,they were randomly divided into the control group and the observation group,48 patients in each group.The control group was treated with Atorvastatin,and the observation group was treated with Telmisartan combined with Atorvastatin,the two groups were treated for 2 months.The differences of cardiac function,glycolipid metabolism and inflammatory indexes between two groups before and after 2 months of treatment,and the treatment safety were evaluated.Result:After 2 months of treatment,the left ventricular ejection fraction(LVEF),early diastolic peak velocity(E peak),E/maximum late diastolic velocity(A peak),and high-density lipoprotein cholesterol(HDL-C)in two groups were higher than those before treatment,and the left ventricular end-diastolic Inner diameter(LVEDD),A peak,triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),glycosylated hemoglobin(HbA1c),fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),C-reactive protein(CRP),interleukin-8(IL-8),interleukin-6(IL-6)levels in two groups were lower than those before treatment,the indexes of the observation group were better than those of the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse drug reactions between two groups(P>0.05).Conclusion:Telmisartan combined with Atorvastatin in the treatment of patients with diabetes and coronary heart disease can promote the recovery of cardiac function,inhibit inflammatory reaction,and have prominent lipid and glucose lowering effects,which is relatively safe.